Epimedium applied in the clinical treatment of osteoporosis patients with periodontitis
2024

Epimedium for Osteoporosis and Periodontitis Treatment

Sample size: 120 publication Evidence: moderate

Author Information

Author(s): Guo Ying, Ge Xu, Wang Wei, Wang Rongrong, Chen Qianmin, Wang Hong

Primary Institution: General Hospital of Shenzhen University

Hypothesis

Epimedium, when used as an adjunct to standard osteoporosis treatment, will enhance BMD and simultaneously reduce periodontal inflammation in patients with coexisting osteoporosis and periodontitis.

Conclusion

Epimedium shows promise as an adjunctive therapy in patients with osteoporosis and periodontitis, contributing to improved BMD, reduced inflammation, and enhanced periodontal health.

Supporting Evidence

  • Patients receiving Epimedium showed significantly greater increases in lumbar spine and proximal femur BMD.
  • Periodontal health metrics improved more in the observation group compared to the control group.
  • The total effective rates for osteoporosis and periodontitis were higher in the observation group.

Takeaway

This study found that a herbal treatment called Epimedium can help people with weak bones and gum disease feel better and healthier.

Methodology

This retrospective study analyzed clinical data from 120 patients with osteoporosis and periodontitis, divided into two groups receiving different treatments.

Limitations

The study may lack geographical diversity and did not control for lifestyle factors that could affect outcomes.

Participant Demographics

Patients were middle-aged and elderly individuals with osteoporosis and periodontitis.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1097/MD.0000000000040837

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication